	US 12,448,654 B2
	Compositions and methods for detecting pancreatic cancer
Jin Song, Baltimore, MD (US); Zhen Zhang, Baltimore, MD (US); and Daniel Wan-Yui Chan, Clarksville, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Jun. 21, 2024, as Appl. No. 18/749,771.
Application 18/749,771 is a continuation of application No. 17/013,989, filed on Sep. 8, 2020, granted, now 12,037,647.
Application 17/013,989 is a continuation of application No. 16/737,084, filed on Jan. 8, 2020, abandoned.
Application 16/737,084 is a continuation of application No. 15/747,780, abandoned, previously published as PCT/US2016/043833, filed on Jul. 25, 2016.
Claims priority of provisional application 62/197,946, filed on Jul. 28, 2015.
Prior Publication US 2025/0043361 A1, Feb. 6, 2025
Int. Cl. G01N 33/00 (2006.01); C07K 14/47 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)

CPC C12Q 1/6886 (2013.01) [C07K 14/4748 (2013.01); G01N 33/57438 (2013.01); C12Q 2600/158 (2013.01)]

6 Claims

1. A method of diagnosing and treating a subject having intraductal papillary mucinous neoplasm (IPMN), the method comprising:

a) detecting in a blood or serum sample from a subject increased levels relative to a healthy subject of four or more markers selected from the group consisting of OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP, wherein the detected markers comprise at least MIA, HSP27, MIC1 and OPN, and

b) determining the subject has intraductal papillary mucinous neoplasm (IPMN) based on the increased level of markers;

c) treating the subject for intraductal papillary mucinous neoplasm (IPMN) which comprises surgery and optionally chemotherapy.